Insomnia Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.58 Billion |
| Market Size (2029) | USD 4.60 Billion |
| CAGR (2024 - 2029) | 5.16 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Insomnia Treatment Market Analysis
The Insomnia Treatment Market size is estimated at USD 3.58 billion in 2024, and is expected to reach USD 4.60 billion by 2029, growing at a CAGR of 5.16% during the forecast period (2024-2029).
Insomnia occurs when individuals face disturbances in their feelings or abilities due to inadequate or poor-quality sleep. Approximately 10% of the global population have insomnia severe enough to be considered a medical issue. While insomnia is typically not life-threatening, there are numerous treatment options available, such as medications and mental health interventions, to address it.
Based on the Sleep Prioritization Survey 2023 conducted by the American Academy of Sleep Medicine (AASM), it was found that approximately 29% of individuals utilize melatonin either occasionally or regularly. The 2022 survey revealed that 64% of Americans relied on some form of substance occasionally or regularly to aid in falling asleep or staying asleep. Of this percentage, 23% use prescription medication, 27% use melatonin, and 20% use marijuana or CBD. The significant impact on individuals' sleep patterns has resulted in an increased demand for insomnia treatment during the pandemic. Despite this, the necessity for insomnia treatment is anticipated to persist even post-pandemic, thereby contributing to the market's growth in the next five years.
The market is projected to experience growth due to the increasing prevalence of insomnia, rising stress levels, and the growing awareness of various treatment options for this condition. As an illustration, the Sleep Foundation 2023 reported that insomnia is a sleep disorder that affects up to 35% of adults. It is defined by difficulties in falling asleep, staying awake during the night, and achieving the desired duration of sleep until the morning. This disorder can lead to significant consequences, including excessive daytime sleepiness, an elevated risk of car accidents, and widespread health issues resulting from sleep deprivation.
The rising stress levels among the global population are another primary driver for the market's growth. According to the Health and Safety Executive report published in 2023, the number of workers reporting work-related stress, depression, or anxiety in the United Kingdom was approximately 875,000. Such high stress among the population is also expected to drive the market's growth. Insomnia rarely occurs on its own and is frequently associated with other illnesses.
Furthermore, innovative product developments for the treatment of insomnia are also expected to contribute to the market's growth. For instance, in June 2022, Pear Therapeutics reported interim follow-up real-world data from a decentralized trail that showed treatment with Somryst, one of the FDA-authorised digital therapeutics for treating chronic insomnia. This device significantly reduced symptoms of insomnia, anxiety, and depression severity.
Thus, factors such as the prevalence of insomnia, rising awareness for treatment, and increasing product launches are expected to contribute to the market's growth during the forecast period. However, misconceptions about the seriousness of insomnia and patients' non-adherence to the treatment are some factors that may limit market growth during the forecast period.
Insomnia Treatment Market Trends
Orexin Antagonist Segment is Expected to Hold a Significant Share in the Market During the Forecast Period
- The orexin antagonist segment is expected to dominate the growth of the segment during the forecast period due to the reduced efficacy and harmful side effects that constrain the use of many treatment options for several patients. Some of the orexin receptor antagonists include suvorexant, lemborexant, and daridorexant. These drugs are potent dual orexin receptor antagonists that block both receptors, i.e., OX1R and OX2R. They stimulate sleep by inhibiting orexin-A and B, neuropeptides that promote wakefulness.
- Suvorexant (MK-4305, Merck) is one of the first of a new class of drugs for treating insomnia known as ORAs (orexin receptor antagonists). The tablets support the natural transition from sleeplessness to sleep by inhibiting the arousal system's wakefulness-promoting orexin neurons. Suvorexant advances sleep onset and sleep maintenance. This distinctive alternative has advantageous permissibility and a restricted side-effect profile.
- The increasing product approvals and product development activities are expected to contribute to the growth of the segment during the forecast period. For instance, in October 2022, Idorsia Pharmaceuticals Japan announced positive top-line results of the Japanese Phase 3 study investigating 25 and 50 mg doses of Idorsia's dual orexin receptor antagonist, daridorexant, in 490 randomized adult and elderly patients (30.1% 65 years) with insomnia.
- Similarly, in February 2024, the first selective orexin-1 receptor antagonist (SO1RA) was investigated during clinical trials. The orexin system consists of two neuropeptides (orexins A and B) and two receptors (OX1 and OX2).
- Due to the apparent benefits associated with the orexin class of drugs, increasing product approvals, and the rising prevalence of insomnia or difficulty falling asleep, the insomnia treatment market is expected to grow steadily during the forecast period.
North America is Expected to Dominate the Insomnia Treatment Market During the Forecast Period
- North America is expected to hold a significant share of the insomnia treatment market. The growing need for sleep disorder treatment in the United States and Canada, coupled with the increasing prevalence of sleep disorders, is expected to drive the market during the forecast period.
- For instance, data published by the government of Canada in June 2022 mentioned that one-third of Canadians were not getting enough sleep, with thousands of people suffering from insomnia and other sleep disorders. Such incidences of sleep disorders among the population in this region are expected to drive the market's growth.
- The increasing government support in the form of funding for insomnia treatment is expected to contribute to the market's growth. For instance, in June 2022, the Minister of Health released funding of USD 2.86 million (CAD 3.8 million) to support research on sleep health and insomnia. The government of Canada supported this initiative through the Canadian Institutes of Health Research (CIHR) in partnership with Esai Limited and Mitacs. Such funding in North America is expected to contribute to the market's growth during the forecast period.
- According to the National Library of Medicine, Biotech Information, in 2023, inadequate sleep resulted in a significant economic cost of over USD 411 billion in the United States. This rise in financial burden is consequently affecting the insomnia treatment market in the country.
- Thus, the growing prevalence of sleep disorders and frequent product launches, coupled with increasing government funding for insomnia treatments, are expected to contribute to the market's growth during the forecast period.
Insomnia Treatment Industry Overview
The insomnia treatment market is fragmented in nature, owing to the presence of multiple manufacturers. The major players in the market are Merck & Co., Ebb Therapeutics, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Electromedical Products International Inc., Takeda Pharmaceutical Company Ltd, Cerêve Inc., and Innovative Neurological Devices.
Insomnia Treatment Market Leaders
-
Pfizer Inc.
-
Sanofi S.A.
-
Takeda Pharmaceutical Company Ltd.
-
Merck & Co.
-
Electromedical Products International Inc.
*Disclaimer: Major Players sorted in no particular order
Insomnia Treatment Market News
- February 2024: Nivasorexant (ACT-539313), the first selective orexin-1 receptor antagonist (SO1RA), was investigated during clinical trials.
- May 2022: Idorsia Ltd received marketing authorization from the European Commission for QUVIVIQ, which was indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.
- January 2022: Idorsia received approval from the US Food and Drug Administration for QUVIVIQ 25 and 50 mg for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Insomnia Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumption and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Stress Due to Highly Active Lifestyles of Individuals
- 4.2.2 Side Effects Due to Certain OTC and Prescription Medication
- 4.2.3 High Usage of Media Devices Before Sleep
-
4.3 Market Restraints
- 4.3.1 Misconceptions about the Seriousness of Insomnia
- 4.3.2 Patient Non-adherence due to Characteristic Side Effects of Insomnia Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Treatment Type
- 5.1.1 By Drug
- 5.1.1.1 Benzodiazepines
- 5.1.1.2 Nonbenzodiazepines
- 5.1.1.3 Orexin Antagonist
- 5.1.1.4 Other Drugs
- 5.1.2 Devices
-
5.2 By Distribution Channel
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Other Distribution Channels
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Merck & Co.
- 6.1.2 Ebb Therapeutics
- 6.1.3 Paratek Pharmaceuticals Inc.
- 6.1.4 Pfizer Inc.
- 6.1.5 Sanofi SA
- 6.1.6 Electromedical Products International Inc.
- 6.1.7 Takeda Pharmaceutical Company Ltd
- 6.1.8 Cerêve Inc.
- 6.1.9 Innovative Neurological Devices
- 6.1.10 Eisai Co. Ltd
- 6.1.11 Meda Consumer Healthcare
- 6.1.12 Purdue Pharma LP
- 6.1.13 Pernix Therapeutics
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityInsomnia Treatment Industry Segmentation
As per the scope of the report, insomnia is a sleep disorder with one or more symptoms that could include fatigue, inability to focus or concentrate, poor memory, mood disturbance, daytime sleepiness, and low motivation or energy. The insomnia treatment market is segmented by treatment type, distribution channel, and geography. Based on the treatment type, the market is segmented into drugs and devices. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for the above segments.
| By Treatment Type | By Drug | Benzodiazepines |
| Nonbenzodiazepines | ||
| Orexin Antagonist | ||
| Other Drugs | ||
| By Treatment Type | Devices | |
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Other Distribution Channels | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Insomnia Treatment Market Research FAQs
How big is the Insomnia Treatment Market?
The Insomnia Treatment Market size is expected to reach USD 3.58 billion in 2024 and grow at a CAGR of 5.16% to reach USD 4.60 billion by 2029.
What is the current Insomnia Treatment Market size?
In 2024, the Insomnia Treatment Market size is expected to reach USD 3.58 billion.
Who are the key players in Insomnia Treatment Market?
Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Merck & Co. and Electromedical Products International Inc. are the major companies operating in the Insomnia Treatment Market.
Which is the fastest growing region in Insomnia Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Insomnia Treatment Market?
In 2024, the North America accounts for the largest market share in Insomnia Treatment Market.
What years does this Insomnia Treatment Market cover, and what was the market size in 2023?
In 2023, the Insomnia Treatment Market size was estimated at USD 3.40 billion. The report covers the Insomnia Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Insomnia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Insomnia Treatment Industry Report
The Global Insomnia Treatment Market Report provides a comprehensive industry overview, highlighting the market trends and market share within the industry. This industry report segments the market by treatment type, distribution channel, and geography, offering valuable market data and market analysis. The report includes an industry analysis that gives insights into market leaders and market growth, supported by industry research and industry statistics.
The market forecast and market outlook are detailed in the report, providing a clear picture of the market segmentation and market value. The industry reports cover the market review and market predictions, emphasizing the market growth and market trends. This report example includes a market report and market research, available as a report PDF for further reference.
The industry information and industry outlook are essential for understanding the market dynamics, with a focus on industry sales and industry size. The report highlights the market segmentation and market forecast, ensuring a thorough market overview and market analysis. The research companies involved have contributed to a detailed market review, making this report a valuable resource for understanding the market value and market predictions.
Overall, the report offers an in-depth look at the market data, market segmentation, and market forecast, providing a comprehensive industry outlook and industry statistics. The report PDF is a useful tool for anyone looking to gain insights into the market trends, market growth, and market leaders in the insomnia treatment industry.
